Matthias Miller PhD

Matthias Miller started to work as a clinical project manager for the BioNTech AG (Mainz, Germany) in August 2014. He is managing the first-in-human clinical trial utilizing polytopic RNA-vaccines targeting mutation-derived neo-antigens. Currently, he focuses on projects that aim at taking the next steps in the clinical development of this personalized vaccine and investigates the implementation of novel technologies into the manufacturing process.